Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Nymox Pharmaceutical Corp (NYMX) Report Updated: Oct 17, 2016 | Print This Page

Get more stock ratings by Louis Navellier

Nymox Pharmaceutical Corp (NYMX)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology

Stock Analysis

Rating: Monthly View

October November December January February March April May June July August September

Rating: Weekly View

This Week: B down upgrade
Last Week: C same no change
Two Weeks Ago: C up downgrade
service keys

Nymox Pharmaceutical Corp© quotemedia

Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of novel drugs and diagnostic products for the aging population. The company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. Its lead drug candidate is NX-1207, which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as completed a Phase II clinical trial for low grade localized prostate cancer. The company also has other drug products in development in the fields of cancer, infectious disease, neurodegenerative diseases, and other areas. It markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Saint Laurent, Canada.